Zorifertinib is under clinical development by Alpha Biopharma and currently in Phase III for Non-Small Cell Lung Cancer. According to GlobalData, Phase III drugs for Non-Small Cell Lung Cancer have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Zorifertinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Zorifertinib overview

Zorifertinib (AZD-3759) is under development for the treatment of non small cell lung cancer (NSCLC) in patients with brain metastasis. It is a small molecule administered orally. The drug candidate targets epidermal growth factor receptor (EGFR).

Alpha Biopharma overview

Alpha Biopharma is a biopharmaceutical company that develops therapeutics to treat cancer. The company investigating its lead product candidate Zorifertinib, a small molecule tyrosine kinase inhibitor to treat epidermal growth factor receptor mutation positive non-small cell lung cancer accompanied by central nervous system metastasis. Its flagship product ND0612 is currently in late stage development for Parkinson’s disease patients experiencing motor fluctuations. The company works in partnership with AstraZeneca Plc, Tigermed Consulting Co Ltd, Paraxel International Corp and other drug companies to advance its pipeline. The company has offices in Beijing and Shanghai. Alpha Biopharma is headquartered in Chaoyang, Beijing, China.

For a complete picture of Zorifertinib’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.